SEATTLE and VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical…
Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 06,…
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the…
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive…
54 Specialty EHR Vendors Across 17 Categories Mark New Entries in the 2024 Black Book Surveys with High Satisfaction Marks…
Marks Ten Years Since First Championing the Promise of SleepTech® at CES WASHINGTON, Jan. 3, 2025 /PRNewswire/ -- National Sleep Foundation…
Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 03,…
IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approvalSP-26 ketamine implants nearing…
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total…
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence…